Figure 4. Overall survival of EGFR-mutated lung adenocarcinoma patients with or without the treatment of EGFR tyrosine kinase inhibitors (TKI) after disease recurrence.
A. all patients; B. stage I-II patients; C. stage III patients.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.